By Justin Petrone

Companies that sell genomic research tools such as microarrays and next-generation sequencing platforms stand to benefit from a new international effort to both uncover the causes of rare genetic diseases and to develop therapies for them.

The International Rare Disease Research Consortium, or IRDiRC, aims to develop diagnostics for every known rare disease by 2020, as well as therapies to treat 200 of them.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.